louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04779359: Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
Official title: The Predictive Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease- A Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19 Disease
Lead sponsor: Shanghai Public Health Clinical Center
Sponsor class: OTHER_GOV
First posted: 2021-03-03
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients were included for this study after excluding patients \<18 years age and without confirmed diagnosis of disease.

Brief summary: To investigate the predictive role of lymphocyte subsets and other laboratory measurements in adult patients with COVID-19.This was a single center, retrospective study that involved adult patients with confirmed diagnosis of COVID-19. Electronic medical records were reviewed. Data including age, sex, symptom from onset to hospital admission and laboratory findings at admission of hospitalized patients with confirmed COVID-19 were extracted and analyzed retrospectively.This study indicates that the levels of lymphocyte subsets (CD4+, and CD8+) are associated with disease progression and severity, along with prognosis in patients with COVID-19.

Detailed description: This was a single center, retrospective study that involved adult patients with confirmed diagnosis of COVID-19. Electronic medical records were reviewed. Data including age, sex, symptom from onset to hospital admission and laboratory findings at admission of hospitalized patients with confirmed COVID-19 were extracted and analyzed retrospectively. Identifying the possible immune factors and laboratory parameters is requisite for the early identification of patients with severe COVID-19 and timely intervention for control of the disease. There is an unmet need to establish robust clinical cutoffs of lymphocyte subsets for predicting risk associated with ICU admission, mechanical ventilation, and mortality in COVID-19 patients. This retrospective study was thus carried out to improve knowledge and clinical utility of lymphocyte subset measurements, together with other laboratory measurements and clinical information, for understanding prognosis in COVID-19 patients. These findings suggest that alterations in lymphocyte subsets and laboratory measurements play a significant role in the progression of COVID-19.

Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of COVID-19 disease.

Exclusion Criteria:

* The patients were excluded patients \<18 years age and without confirmed diagnosis of disease.

Primary outcomes:
measure: Correlation of CD4+ and CD8+ T cell absolute counts to disease outcomes
timeFrame: 2021.02-2021.08
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00540059: Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial
Official title: Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Carcinoma
Keywords: Prostate carcinoma
LHRH
Zoladex
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-10-05
Enrollment: 1950
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions


Eligibility criteria: Inclusion Criteria:

* Patients with PCa, who will be treated with Zoladex 10,8 SafeSystem based on the current SPC

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: H Brasch
role: STUDY_DIRECTOR
References:
Clinical trial NCT02011659: Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy
Official title: A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Uterine Myoma, Ovary Neoplasm, Adenomyosis
Keywords: Ramosetron, postoperative nausea and vomiting, laparoscopy
Lead sponsor: National Health Insurance Service Ilsan Hospital
Sponsor class: OTHER
First posted: 2013-12-13
Enrollment: 128
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare postoperative nausea and vomiting (PONV) and perioperative outcomes of gynecologic patients undergoing laparoscopic surgery after scheduled administration of intravenous Ramosetron during hospital stays.

* Randomized controlled arm : Placebo versus Ramosetron injection
* Administration schedule : immediate postoperative status, 12 hrs after surgery, 36hrs after surgery

Detailed description: Surgical outcomes including operative time, blood loss, Hb change, postoperative pain, nausea/vomiting scale, times of rescue therapy, and complications

Eligibility criteria: Inclusion Criteria:

* Age: 18\< or =, = or \<70 with benign gynecologic disease
* ASA-Class I-II
* No-definite malignancy by US, CT/MRI, CA 125 \< 500IU/ml
* Non-smoker

Exclusion Criteria:

* Conversion to laparotomy
* Hx of malignancy
* Smoker
* Suspicious malignancy

Primary outcomes:
measure: Incidence or intensity of PONV
timeFrame: during postoperative hospital stays (2 days)
Secondary outcomes:
measure: Adverse reaction associated with Ramosetron injection
timeFrame: Postoperatvie 7 days (at OPD based)
Other outcomes:
Locations:
city: Goyang-si
country: Korea, Republic of
facility: National Health Insurance Service Ilsan Hospital
Study officials:
References:
citation: Li SC, Wang Y, Choi SJ, Jung YS, Han KH, Chung IB, Lee SH. Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study. Obstet Gynecol Sci. 2019 Sep;62(5):344-351. doi: 10.5468/ogs.2019.62.5.344. Epub 2019 Jul 23.
Clinical trial NCT04415359: Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period
Official title: Evaluation of the Evolution of Pregnancies in the First Trimester Following a Medically Assisted Procreation (MAR) Management During a COVD-19 Pandemic Period
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid-19
Keywords: COVID-19
SARS-CoV-2
ARDS
ICU
Pregnant women
Pregnancy
Fetus
Middle East Respiratory Syndrome
MERS
Maternal respiratory impairment
Medical Assisted Procreation
MAR
Frozen embryos
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2020-06-04
Enrollment: 700
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient included in MAR protocol aged between 18 and 43 years of age who has already signed a consent to management

Brief summary: Because of the physiological changes inherent in pregnancy, pregnant women with lower respiratory tract infections often have more worrisome outcomes compared to non-pregnant individuals, including a higher rate of hospital and intensive care unit admissions.


Eligibility criteria: Inclusion Criteria:

* Patient included in a Medically Assisted Procreation (MAR) protocol aged between 18 and 43 years of age
* Patient who has already signed a consent to management

Exclusion Criteria:

* Patient who expressed opposition to participating in the study

Primary outcomes:
measure: Study of the evolution of pregnancies in the first trimester following MAR management during a COVD-19 pandemic period
timeFrame: 12th week of Amenorrhea
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service Clinico biologique d'Assistance Médicale à La Procréation
Study officials:
References:
Clinical trial NCT00840359: Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis
Official title: Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Cutaneous Leishmaniasis
Keywords: Cutaneous leishmaniasis
Photodynamic therapy
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2009-02-10
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the project is to determine whether daylight activated photodynamic therapy is effective in treating cutaneous leishmaniasis caused by L. major and L. tropical.

PDT is classically performed as a two-step procedure in which MAL application to the lesion constitutes the first step, and PpIX activation by light of appropriate wavelength from an artificial light source constitutes the second step. Based on the knowledge that red and blue light required to activate PpIX are part of the daylight spectrum, the investigators postulated that effective PpIX activation can be obtained by exposure of the MAL treated lesions to daylight thus substantially simplifying the PDT procedure by omitting the 3 hour incubation period and the subsequent exposure to artificial light. In accord, in a recent study the investigators showed that daylight-activated PDT (DA-PDT) was as effective as conventional MAL-PDT in treating precancerous actinic keratoses lesion. Furthermore the investigators found that DA-PDT is significantly less painful than conventional MAL-PDT.

The investigators now propose to study the efficacy of DA-PDT in the treatment of cutaneous leishmaniasis. DA-PDT has obvious advantages to conventional leishmania treatment forms:

As opposed to most of the available treatment options, DA-PDT is a self-administered procedure that does not require the assistance of medical personnel. Secondly, judged by our experience with MAL-PDT, only few treatment sessions are required for effective parasite killing as opposed to the prolonged procedures usually required for treatment of leishmaniasis. Third, PDT has the far the best safety profile of all available treatment options.


Eligibility criteria: Inclusion Criteria:

* At least 2 skin lesions with leishmania caused by L. major or L. tropica

Exclusion Criteria:

* Pregnant or lactating women

Primary outcomes:
measure: Eradiation of amastigotes
timeFrame: 3 months following last treatment session
Secondary outcomes:
measure: Clinical healing
timeFrame: 3 months following last treatment session
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Claes D Enk, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00702559: Design the Home Care Platform for the Monitoring of A Hemodialysis Arteriovenous Graft by Intelligent Physiological Signal
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Renal Dialysis
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2008-06-20
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 50 prosthetic dialysis accesses on upper extremities

Brief summary: Most patients with end-stage renal disease require hemodialysis. An arteriovenous fistula (AVF) or a prosthetic arteriovenous graft (AVG) is the preferred accesses for this. After its surgical creation, the fistular vein immediately faces a tremendous blood flow and the venous lumen is gradually dilated and the wall thickened, producing an access that can be routinely needled and deliver sufficient blood flow for dialysis. However, many hemodialysis patients will experience access stenosis, dysfunction, and even thrombosis, which are the most common complications of a hemodialysis access.

Most physicians, in-charge nurses of the hemodialysis unit, patient, and/or the family use traditional stethoscope as a convenient method to evaluate the patency and function of a hemodialysis access before, during, and after each session of dialysis. The acoustic signal of an access is always affected by environmental noises, non-specific in nature, and the sensitivity to detect stenosis is very low.

With the development and use of electronic stethoscope, the proprietary ambient noise acoustically cancels out an average of 75% of distracting room noise, greatly enhancing overall utility. However, the output acoustic signals are still apprehended by the ear, which is the main source of bias and errors of detection.

Our study purpose is to apply the signal processing technology to transfer the acoustic signals into simple visual signals that provide an easy way to read. It can be used by a professional medical staff, a non-professional person responsible for taking care, or even the patient himself, disability or not, as an early screening detector of stenosis or dysfunction of a hemodialysis access.


Eligibility criteria: Inclusion Criteria:

* prosthetic grafts with clinical signs of dysfunctions or malfunctions and were referred for angiographic evaluations.

Exclusion Criteria:

* autologous arteriovenous accesses or known thrombosed accesses.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Far Eastern Memorial Hospital
Study officials:
References:
Clinical trial NCT05825859: Total Body Perfusion in Patients With Chest Pain
Official title: Total Body Perfusion in Patients With Chest Pain
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Coronary Artery Disease
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2023-04-24
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Finnish people that have history of chest pain and for which there have been done CTA which shows a possibility for obstructive coronary artery disease. All people in the study population have came to a diagnostic radiowater imgaing to know if there is significant obsturction of the coronary arteries.

Brief summary: The Purpose of this study is to better understand changes in obstructive coronary artery disease in different organs other than the heart such as the brain and the kidneys using a new generation total body PET scanner.

Detailed description: Patients with chest pain and suspected CAD will be studied using total body PET imaging with O15-water perfusion imaging

Eligibility criteria: Inclusion Criteria:

* Documented history of chest pain with CT imaging showing a potential for obstructive coronary artery disease
* Ability to sustain adenosine injection 0.14 mg/kg/min

Exclusion Criteria:

* Second or third degree AV-block without pacemaker
* Sick sinus syndrome
* Consumption of coffee or aminophylline within 12 hours of administration
* Recent use of dipyridmole or dipyridamole-containing medications
* Known hypersensitivity to adenosine
* Unstable acute MI or acute coronary artery syndrome, and prior cardiac transplantation
* Active wheezing and bronchospasm
* Sinus bradycardia with HR\<40 bmp

Primary outcomes:
measure: Perfusion in heart, brain and kidneys during rest and adenosine stress, and their associations with psychologic factors and anginal symptoms
timeFrame: The imaging day
Secondary outcomes:
measure: The association between perfusion in heart, brain and kidneys, and adverse events during five year follow-up
timeFrame: Five year follow-up after the imaging
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Juhani Knuuti, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01138800: Assessing Chronic Pain Conditions in Patients (Pts) With and Without (w&wo) Interstitial Cystitis
Official title: Assessing Chronic Pain Conditions in Patients With and Without Interstitial Cystitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interstitial Cystitis
Lead sponsor: William Beaumont Hospitals
Sponsor class: OTHER
First posted: 2010-06-07
Enrollment: 666
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women over 18 years of age with IC identified from the investigators practice (cases); women over 18 years of age without IC (controls)

Brief summary: Interstitial cystitis (IC) is a chronic disorder with significant symptoms of urinary urgency, frequency and pelvic pain. IC is more prevalent in women than men. Similar to other chronic pain syndromes such such as irritable bowel syndrome (IBS) and fibromyalgia, the cause of IC is not fully understood. Two subtypes of IC have been identified: classic IC (ulcerative IC) where visible ulcers exist in the bladder and non ulcerative IC, where bladder abnormalities are not apparent but significant bladder-related symptoms exist. We hypothesize that ulcerative IC is a disease of the bladder whereas non ulcerative IC is a more generalized and centrally-mediated chronic pain syndrome similar to IBS and fibromyalgia. To test this hypothesis, we will compare the presence of pain conditions/symptoms in ulcerative vs. non ulcerative IC women vs. community dwelling women (controls) without an IC diagnosis.


Eligibility criteria: Inclusion Criteria:

* Women over 18 years of age with IC identified by investigator (cases);
* Women over 18 years of age with IC (controls)

Exclusion Criteria:

* Male gender;
* subjects less than 18 years of age

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Royal Oak
country: United States
facility: William Beaumont Hospital - Urology Research
state: Michigan
Study officials:
affiliation: William Beaumont Hospitals
name: Kenneth M Peters, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05822700: Outcome Of Using Transfixing K Wire ln DDH With Hypoplastic Head And Severe Generalised Ligamentous Laxity
Official title: Outcome Of Using Transfixing Hip K Wire ln Developmental Dysplasia Of Hip With Hypoplastic Head And Severe Generalised Ligamentous Laxity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Developmental Dysplasia of the Hip
Keywords: Developmental dysplasia of the study
Kirschner wire
Hypoplastic Head
Ligamentous laxity
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-04-21
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the outcome of using transfixing hip k wire in Developmental dysplastic hip in patients with hypoplastic head and severe generalised ligamentous laxity.

Detailed description: The goal of treatment in developmental dysplasia of the hip (DDH) is to obtain and maintain a stable concentric reduction.

Surgical treatment is done by open reduction through a medial approach or anterolateral approach with pelvic osteotomy,capsulorhaphy, femoral shortening and derotational osteotomy.

Transfixing the femoral head with Kirschner wire during open reduction has long been thought to provide stability to the hip without damaging the femoral head or the acetabulum and to decrease the risk or re-dislocation.

The aim of this study is to assess the effect of transfixing the hip with Kirschner wire during the operative treatment of hip dysplasia in children after the walking age on the final radiological and clinical results and to compare the risks with the benefits of adding this step.

Eligibility criteria: Inclusion Criteria:

1. Patients older than 1 year and younger than 7
2. Patients with hypoplastic head
3. Patients with severe ligamentous laxity (Beighton score ≥ 4)

Exclusion Criteria:

1. Patients younger than 1 year and older than 7 years old.
2. Beighton score \< 4
3. Secondary hip dislocation (neuromuscular disorder) as cerebral palsy , myelodysplasia or arthrogryposis.

Primary outcomes:
measure: Modified McKay's criteria
timeFrame: 1 year
Secondary outcomes:
measure: Complications
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Hesham Elbaseet, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Harsanyi S, Zamborsky R, Krajciova L, Kokavec M, Danisovic L. Developmental Dysplasia of the Hip: A Review of Etiopathogenesis, Risk Factors, and Genetic Aspects. Medicina (Kaunas). 2020 Mar 31;56(4):153. doi: 10.3390/medicina56040153.
citation: Sankar WN, Young CR, Lin AG, Crow SA, Baldwin KD, Moseley CF. Risk factors for failure after open reduction for DDH: a matched cohort analysis. J Pediatr Orthop. 2011 Apr-May;31(3):232-9. doi: 10.1097/BPO.0b013e31820c9b31.
citation: Kamath SU, Bennet GC. Re-dislocation following open reduction for developmental dysplasia of the hip. Int Orthop. 2005 Jun;29(3):191-4. doi: 10.1007/s00264-005-0654-6. Epub 2005 Apr 7.